No Data
FRONTEO, casting and others.
Acquired all shares of Arnetts, which is engaged in in-house support (low-code platform related to Mendix) systems, and made it a wholly-owned subsidiary. The large exercise of the 32nd subscription rights of Medrec (with exercise price adjustment provisions) will have 3.2 million shares delivered starting from the 24th. Released 1-inch single crystal wafers for the Diamond from EDP. Formed a business partnership with Wiz, which is involved in support businesses like Caster DX.
Medilex has been found to have a Shareholding of over 5% in Long Corridor.
It has been revealed that Long Corridor Asset Management (Long Corridor) holds more than 5% of Medrex<4586.T>'s Stocks. According to the large shareholder report submitted by Long Corridor after the market closed on the 17th, the company holds 12.3 million shares (shareholding ratio of 20.72%). The purpose of the shareholding is for pure investment. The closing price on the 17th was 61 yen, down 1 yen from the previous day. Provided by Wealth Advisor Inc.
Express News | The Long Corridor reported a shareholding of 20.72% in Medrex (4586.JP).
Stocks that moved and those that were traded in the front market.
*Shinkong Electric Industry <6967> 8781 +1176, the buying back situation is still leading. *GMO Internet <4784> 1470 +141, updating highs, and moving lightly within domestic stocks for price range opportunities. *KADOKAWA <9468> 3838 +224, a subsidiary announced a new product for Switch 2. *United Arrows <7606> 2244 +126, the same-store sales for March had double-digit revenue growth. *Nishimatsuya Options Chain <7545>
Medrex rebounded after eight days, as the FDA accepted the application for a neuropathic pain treatment drug co-developed with DWTI.
Medrex <4586.T> rebounded for the first time in eight days after a period of no change, temporarily reaching 77 yen, which is an increase of 9 yen. After the close on the 2nd, the company announced that its group and De-Western Therapeutics Institute (DWTI) <4576.T> had resubmitted an application for new drug approval to the FDA (U.S. Food and Drug Administration) for the treatment of postherpetic neuralgia "MRX-5LBT," and it was accepted, which is viewed as noteworthy. According to the company, "MRX-5LBT" utilizes ionic liquids.
D. Western Therapeutics' Lidocaine Patch NDA Accepted by FDA
